Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Curis Inc (CRIS)

Curis Inc (CRIS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,147
  • Shares Outstanding, K 13,735
  • Annual Sales, $ 10,910 K
  • Annual Income, $ -43,390 K
  • EBIT $ -34 M
  • EBITDA $ -34 M
  • 60-Month Beta 3.02
  • Price/Sales 0.99
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.59
  • Number of Estimates 2
  • High Estimate -0.45
  • Low Estimate -0.72
  • Prior Year -1.25
  • Growth Rate Est. (year over year) +52.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9201 +10.86%
on 02/06/26
1.2100 -15.70%
on 02/13/26
+0.1094 (+12.01%)
since 02/05/26
3-Month
0.7710 +32.30%
on 01/07/26
1.4090 -27.61%
on 12/09/25
-0.3300 (-24.44%)
since 12/05/25
52-Week
0.7710 +32.30%
on 01/07/26
3.1800 -67.92%
on 03/17/25
-1.9500 (-65.66%)
since 03/05/25

Most Recent Stories

More News
Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP

CRIS : 1.0200 (-0.97%)
Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

LEXINGTON, Mass. , Jan. 7, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...

CRIS : 1.0200 (-0.97%)
Curis Provides Updated Data from its Frontline AML Triplet Study

5 of 8 patients (62.5%) achieved Undetectable MRD (uMRD)

CRIS : 1.0200 (-0.97%)
Curis to Present at Upcoming 30th Annual SNO Meeting

LEXINGTON, Mass. , Nov. 14, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...

CRIS : 1.0200 (-0.97%)
Curis: Q3 Earnings Snapshot

Curis: Q3 Earnings Snapshot

CRIS : 1.0200 (-0.97%)
Curis Provides Third Quarter 2025 Business Update

Management to host conference call and webcast today at 4:30 p.m. ET

CRIS : 1.0200 (-0.97%)
Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025

LEXINGTON, Mass. , Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...

CRIS : 1.0200 (-0.97%)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass. , Oct. 3, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...

CRIS : 1.0200 (-0.97%)
Curis to Present at Upcoming Healthcare Conferences in September

LEXINGTON, Mass. , Sept. 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...

CRIS : 1.0200 (-0.97%)
Curis: Q2 Earnings Snapshot

Curis: Q2 Earnings Snapshot

CRIS : 1.0200 (-0.97%)

Business Summary

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate...

See More

Key Turning Points

3rd Resistance Point 1.1967
2nd Resistance Point 1.1533
1st Resistance Point 1.0867
Last Price 1.0200
1st Support Level 0.9767
2nd Support Level 0.9333
3rd Support Level 0.8667

See More

52-Week High 3.1800
Fibonacci 61.8% 2.2598
Fibonacci 50% 1.9755
Fibonacci 38.2% 1.6912
Last Price 1.0200
52-Week Low 0.7710

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar